GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice
These results suggest caution in over-interpreting GAD-Abs values. Better biomarkers for identifying patients with immunotherapy responsive GAD-Ab disease are needed.
Authors
- Héctor García‐Moreno (ORCID: https://orcid.org/0000-0002-0697-3271)
- Melanie Hart (ORCID: https://orcid.org/0000-0002-7396-1916)
- Andrew J. Church (ORCID: https://orcid.org/0009-0009-4562-0338)
- Michael S. Zandi (ORCID: https://orcid.org/0000-0002-9612-9401)
- Gilbert Thomas‐Black (ORCID: https://orcid.org/0000-0002-4410-8772)
- Zofia Fleszar
- Paola Giunti (ORCID: https://orcid.org/0000-0003-3508-4788)
- Angela Vincent (ORCID: https://orcid.org/0000-0003-2395-8695)
- Michael Peter Lunn (ORCID: https://orcid.org/0000-0003-3174-6027)
- Rachel Brown (ORCID: https://orcid.org/0000-0002-9932-0228)
- Miles Chapman
- Michael Chou
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Hertie Institute for Clinical Brain Research (DE)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1007/s00415-025-12926-3
- Citations
- 8
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 11.11
Funders
- National Brain Appeal
- Medical Research Council
- University College London Hospitals Biomedical Research Centre